A Comprehensive Guide to ICD-10 Codes for Elevated Liver Function Tests

A routine physical, a pre-operative workup, or an investigation into non-specific symptoms like fatigue—the journey often begins with a simple blood draw. Days later, the results arrive, and amidst the sea of values, a cluster of asterisks or bolded text draws the eye: the liver function tests (LFTs) are elevated. This common clinical finding is a silent alarm bell from one of the body’s most vital and resilient organs. It is a signal that can mean anything from a transient, inconsequential anomaly to the first harbinger of a serious, life-altering disease. For the clinician, the immediate task is diagnostic: What is causing this? For the medical coder, biller, and healthcare administrator, a parallel challenge arises: How do we accurately, specifically, and compliantly translate this clinical picture into the universal language of medical classification—the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM)?

This article is designed to be the definitive guide at this critical intersection. We will embark on a detailed exploration that moves far beyond the simplistic code for “elevated LFTs.” We will dissect the physiology behind the lab values, master the structure and intent of the ICD-10-CM system, and delve into the nuanced coding for the vast spectrum of diseases that manifest with abnormal liver chemistry. Our goal is not only to provide the correct codes but to foster a deeper understanding that empowers clinicians to document more effectively and coders to query more intelligently. In an era of value-based care and heightened regulatory scrutiny, precision in diagnosis coding is not merely an administrative task; it is an integral component of high-quality patient care. Let us begin by understanding what these tests are truly measuring.

Chapter 1: The Foundation – Understanding Liver Function Tests (LFTs)

The term “Liver Function Test” is, in many ways, a misnomer. A standard LFT panel is less a direct measure of the liver’s functional capacity and more a series of biomarkers that indicate hepatocyte injury, biliary obstruction, and synthetic function. To interpret and code these findings correctly, one must first understand what each component represents.

The Hepatobiliary System: A Master of Multitasking

The liver is a metabolic powerhouse. Its responsibilities include:

• Detoxification: Metabolizing drugs, alcohol, and metabolic waste.

• Protein Synthesis: Producing albumin and clotting factors.

• Bile Production: Essential for the digestion and absorption of fats.

• Glucose Homeostasis: Storing glycogen and regulating blood sugar.

• Storage: Holding vitamins, minerals, and iron.

When LFTs are elevated, it signifies an insult that is disrupting one or more of these complex functions.

Deconstructing the LFT Panel: Enzymes, Proteins, and Bilirubin

A typical hepatic panel includes:

• Aminotransferases (Markers of Hepatocellular Injury):

  • Alanine Aminotransferase (ALT): Primarily found in the liver. An elevated ALT is highly specific for liver cell damage.

  • Aspartate Aminotransferase (AST): Found in the liver, heart, muscle, and kidneys. Less specific for liver injury than ALT.

• Alkaline Phosphatase (ALP) (Marker of Cholestasis): An enzyme present in the bile ducts and bones. Elevation suggests biliary obstruction or bone disease. A concurrent elevation in Gamma-Glutamyl Transferase (GGT) can help confirm the liver as the source.

• Bilirubin (Marker of Hepatic Function and Bile Flow):

  • Total Bilirubin: The sum of unconjugated (indirect) and conjugated (direct) bilirubin.

  • Direct Bilirubin: Elevated in conditions where the liver is processing bilirubin but cannot excrete it, such as biliary obstruction.

  • Indirect Bilirubin: Elevated in pre-hepatic conditions like hemolysis or Gilbert’s syndrome.

• Albumin and Prothrombin Time (PT/INR) (Markers of Synthetic Function):

  • Albumin: A protein made by the liver. Low levels suggest chronic liver disease or severe acute liver failure.

  • Prothrombin Time (PT/INR): Clotting factors are produced by the liver. A prolonged PT/INR indicates impaired synthetic function, which can be acute or chronic.

Patterns of Injury: Hepatocellular vs. Cholestatic

The relative elevation of these markers creates patterns that guide the diagnostic workup:

• Hepatocellular Pattern: Marked elevation in ALT and AST (often in the 100s or 1000s) with minimal rise in ALP. Seen in viral hepatitis, ischemic hepatitis, and drug-induced liver injury.

• Cholestatic Pattern: Marked elevation in ALP and bilirubin with minimal rise in aminotransferases. Seen in biliary obstruction, primary biliary cholangitis, and drug-induced cholestasis.

• Mixed Pattern: Elevations in both aminotransferases and ALP. Seen in some cases of drug toxicity or infiltrative diseases.

( Common LFT Patterns and Their Associated Etiologies)

Infographic: A flow chart showing the diagnostic thought process from an elevated LFT panel, branching into hepatocellular and cholestatic pathways, and further subdividing based on additional history and testing.

Chapter 2: The World of ICD-10-CM – A Primer for the Practitioner

Before we assign a single code, it is imperative to understand the philosophy and structure of the modern coding system.

Beyond Billing: The Importance of Accurate Diagnosis Coding

While reimbursement is a primary driver, ICD-10-CM codes serve a much broader purpose:

• Patient Care: Facilitates communication between providers and ensures continuity of care.

• Population Health: Tracks disease prevalence, outbreaks, and public health trends.

• Research: Provides data for clinical trials, outcomes research, and epidemiological studies.

• Quality Metrics: Used to assess hospital and physician performance and patient safety.

• Risk Adjustment: Determines the complexity of a patient population for payment models.

Structure and Logic of the ICD-10-CM System

ICD-10-CM is alphanumeric, with codes ranging from 3 to 7 characters. The first character is always a letter, followed by a combination of numbers and letters.

• Chapter: Codes are grouped into chapters based on etiology or body system (e.g., Chapter 1: Infectious Diseases, Chapter 11: Diseases of the Digestive System).

• Category: The first three characters define the general category of the disease.

• Subcategory and Subclassification: Characters 4 through 7 provide increasing specificity regarding etiology, anatomical site, severity, and other clinical details.

For example, in code K70.30:

• K70: Category for Alcoholic Liver Disease

• K70.3: Subcategory for Alcoholic Hepatitis

• K70.30: Subclassification for Alcoholic Hepatitis without Ascites

This hierarchical structure demands specificity. Using an unspecified code when a more specific one is available is clinically inaccurate and can have financial and administrative consequences.

Chapter 3: The Core Challenge – ICD-10-CM Code R94.5 “Abnormal Liver Function Studies”

This is the code most directly associated with the phrase “elevated LFTs.” Its official descriptor in the ICD-10-CM manual is: “Abnormal results of function studies of liver”.

A Sign, Not a Diagnosis: The Appropriate Use of R-Codes

Code R94.5 resides in Chapter 18 of ICD-10-CM, “Symptoms, Signs, and Abnormal Clinical and Laboratory Findings, Not Elsewhere Classified.” This is a critical distinction. R94.5 is a sign code, not a diagnosis code. It should be used when the elevated LFTs are an unexplained finding, and the underlying cause has not yet been determined.

Clinical Scenarios Where R94.5 is Justified

1. Initial Encounter for Asymptomatic Elevation: A patient is found to have mildly elevated ALT on a routine screening. The physician’s plan is to repeat the test and obtain a history and further workup. The final diagnosis is “abnormal LFTs, etiology unknown.”

2. Monitoring a Known Condition: A patient with a history of statin use is being monitored for potential hepatotoxicity. The encounter is specifically for the purpose of reviewing the LFT results, which remain stable and mildly elevated. The reason for the test is the monitoring, not a new acute disease.

3. Incidental Finding Unrelated to Current Encounter: A patient presents for an upper respiratory infection, and routine labs show a slight LFT elevation that the physician deems non-urgent and plans to address at a follow-up visit.

The Pitfalls of Over-Reliance on R94.5

Using R94.5 as a default is a common but significant error. It is clinically vague and fails to capture the patient’s true condition. Payers may deny claims if a more definitive diagnosis is available but not coded. Furthermore, it provides no useful data for tracking disease outcomes. The goal of clinical care and coding is always to replace a sign code (R94.5) with an etiologic diagnosis code.

Chapter 4: From Abnormality to Diagnosis – Specifying the Underlying Cause

This is the heart of accurate coding. The following sections will explore the primary diagnostic categories and their corresponding ICD-10-CM codes.

Section 4.1: Alcoholic Liver Disease (K70.-)

This category requires clear documentation of the causal relationship between alcohol use and the liver disease.

• K70.0 – Alcoholic fatty liver: Simple steatosis due to alcohol.

• K70.10 – Alcoholic hepatitis without ascites: Acute inflammation of the liver from alcohol.

• K70.11 – Alcoholic hepatitis with ascites: Alcoholic hepatitis accompanied by fluid accumulation in the abdomen.

• K70.2 – Alcoholic fibrosis and sclerosis of liver: Early scarring.

• K70.30 – Alcoholic cirrhosis of liver without ascites: End-stage scarring.

• K70.31 – Alcoholic cirrhosis of liver with ascites.

• K70.40 – Alcoholic hepatic failure without coma: Severely impaired function.

• K70.41 – Alcoholic hepatic failure with coma.

• K70.9 – Alcoholic liver disease, unspecified: A less desirable code to be used only if the documentation lacks specificity.

Coding Note: Always code also for the alcohol use disorder (F10.-) if documented.

Section 4.2: Toxic Liver Disease (K71.-)

This is a complex and highly specific category for drug-induced liver injury (DILI). The codes are based on the histologic pattern of injury.

• K71.0 – Toxic liver disease with cholestasis: e.g., from anabolic steroids, chlorpromazine.

• K71.1 – Toxic liver disease with hepatic necrosis: e.g., from acetaminophen overdose, halothane.

• K71.2 – Toxic liver disease with acute hepatitis: A general inflammatory pattern.

• K71.5 – Toxic liver disease with chronic persistent hepatitis.

• K71.6 – Toxic liver disease with chronic lobular hepatitis.

• K71.7 – Toxic liver disease with chronic active hepatitis.

• K71.9 – Toxic liver disease, unspecified.

Crucial Coding Note: You must use an additional code from categories T36-T50 with fifth or sixth character 5 to identify the causative drug (e.g., T39.15A for Adverse effect of propionic acid derivatives, initial encounter, for ibuprofen-induced injury).

Section 4.3: Viral Hepatitis (B15-B19)

Coding for viral hepatitis requires knowing the type of virus (A, B, C, etc.) and the clinical stage (acute vs. chronic).

• B15.9 – Hepatitis A without hepatic coma: Hepatitis A is typically acute.

• B16.9 – Acute hepatitis B without delta-agent and without hepatic coma.

• B17.10 – Acute hepatitis C without hepatic coma.

• B18.2 – Chronic viral hepatitis C: This is the code for the vast majority of patients with ongoing HCV infection.

• B19.10 – Unspecified viral hepatitis B without hepatic coma: Use only if the provider cannot specify acute or chronic.

• B19.20 – Unspecified viral hepatitis C without hepatic coma.

Coding Note: For chronic hepatitis B, B18.1 is used. Carrier status is coded to Z22.5-.

Section 4.4: Non-Alcoholic Fatty Liver Disease (NAFLD) and NASH (K76.0, K75.81)

This is one of the most common causes of elevated LFTs in the developed world.

• K76.0 – Fatty (change of) liver, not elsewhere classified: This is the code for simple steatosis or NAFLD without significant inflammation.

• K75.81 – Non-alcoholic steatohepatitis (NASH): This code is used for the more aggressive form characterized by inflammation and ballooning, which can lead to fibrosis and cirrhosis.

Coding Note: The distinction between NAFLD (K76.0) and NASH (K75.81) is a clinical/pathological one. Coders must rely on the provider’s specific documentation.

Section 4.5: Autoimmune and Cholestatic Liver Diseases

• Autoimmune Hepatitis (AIH): Coded to K75.4.

• Primary Biliary Cholangitis (PBC), formerly Cirrhosis: Coded to K74.3.

• Primary Sclerosing Cholangitis (PSC): Coded to K83.01.

• Secondary Biliary Cirrhosis: Coded to K74.4.

Section 4.6: Cirrhosis and Its Sequelae (K74.-, K76.7, I85.-)

Cirrhosis is the final common pathway of many chronic liver diseases. Coding must reflect the etiology of the cirrhosis if known, and any complications.

• K74.60 – Unspecified cirrhosis of liver: A less specific code. Always try to use a more specific etiology code first (e.g., K70.30, B18.2, K74.3).

• K76.7 – Hepatorenal syndrome: A serious complication.

• I85.10 – Secondary esophageal varices without bleeding: Code also the underlying cirrhosis.

• I85.11 – Secondary esophageal varices with bleeding.

• R18.- – Ascites: Code also the underlying liver disease.

Section 4.7: Less Common, But Critical, Etiologies

• Hemochromatosis: E83.11-

• Wilson’s Disease: E83.01

• Alpha-1 Antitrypsin Deficiency: E88.01

• Ischemic Hepatitis (“Shock Liver”): K76.89 – Other specified diseases of liver. The clinical context (e.g., post-cardiac arrest) must be documented.

• Congestive Hepatopathy (from Heart Failure): K76.1 – Chronic passive congestion of liver.

Chapter 5: The Art and Science of Clinical Documentation Improvement (CDI)

The coder can only code what the provider documents. Clear, specific, and consistent documentation is the linchpin of accurate coding.

Bridging the Gap Between Clinician and Coder

A CDI program encourages a partnership where coders and CDI specialists can query physicians for clarification, leading to a more accurate representation of the patient’s severity of illness and risk of mortality.

Essential Elements for a “Code-Ready” Diagnosis

Instead of documenting “elevated LFTs,” the provider should specify:

• The Etiology: “Elevated LFTs secondary to alcoholic hepatitis.”

• The Specific Disease Process: “Patient presents with newly diagnosed autoimmune hepatitis.”

• Acuity: “Acute hepatitis B infection.” or “Chronic HCV with elevated transaminases.”

• Severity and Complications: “Alcoholic cirrhosis, decompensated, with ascites and hepatic encephalopathy.”

• Causative Agent (for DILI): “Drug-induced liver injury, pattern of hepatocellular necrosis, due to course of X medication.”

The Power of Specificity: A Case Study

• Poor Documentation: “Patient seen for follow-up of elevated LFTs. Plan: Continue monitoring.”

  • Likely Code: R94.5

• Good Documentation: “Patient seen for follow-up of elevated LFTs. The pattern is consistent with steatohepatitis. Diagnosis: Non-alcoholic steatohepatitis (NASH).”

  • Correct Code: K75.81

• Excellent Documentation: “Patient with history of chronic hepatitis C (genotype 1a), previously treated and achieving SVR, presents with elevated ALT/AST. Ultrasound confirms fatty liver. Diagnosis: NAFLD with simple steatosis, status-post cured HCV.”

  • Correct Codes: K76.0 (NAFLD), Z86.19 (Personal history of other infectious and parasitic diseases – for the cured HCV).

Chapter 6: Advanced Coding Scenarios and Complex Cases

Real-world medicine is often messy. Here’s how to handle complex situations.

Multiple Etiologies and Comorbid Conditions

A patient can have more than one cause for elevated LFTs. Code all documented diagnoses that are relevant to the current encounter, sequencing the one that is the primary reason for the visit first.

• Example: A patient is admitted for management of acute alcoholic hepatitis (K70.10). The workup also reveals chronic hepatitis B (B18.1). Both codes would be assigned, with K70.10 sequenced first.

Post-Procedural and Iatrogenic Elevations

If LFTs elevate after a procedure like a cholecystectomy, the code depends on the cause.

• Bile Duct Injury: Code the injury (e.g., T81.22-).

• Post-cholecystectomy Syndrome: K91.5

• Drug-induced (from post-op antibiotics): K71.- and the T-code for the drug.

The Patient with Persistent Elevation of Unknown Etiology

After a thorough workup, if no cause is found, the appropriate code remains R94.5. The documentation should reflect the extent of the negative workup (e.g., “elevated LFTs, idiopathic, after extensive serologic and radiologic evaluation”).

Chapter 7: The Future of Liver Disease Classification – A Glimpse Beyond ICD-10

The transition to ICD-11 is underway, bringing even greater specificity.

• ICD-11: Includes more detailed codes for types of drug-induced liver injury, stages of fibrosis, and etiologies of cirrhosis. For example, code DB92.1 for “Alcoholic steatohepatitis” is distinct from DB92.2 for “Alcoholic liver cirrhosis.”

• Precision Medicine: As our understanding of genetic subtypes of diseases like NASH and PBC grows, future classifications may incorporate molecular markers to guide therapy and prognosis, which will inevitably be reflected in future coding systems.

Conclusion

Accurately coding for elevated liver function tests is a critical skill that transcends mere administrative duty. It demands a synergistic understanding of hepatic physiology, clinical diagnostics, and the detailed hierarchy of the ICD-10-CM system. The journey from a nonspecific sign (R94.5) to a precise etiologic diagnosis code is the journey of medicine itself—a progression from symptom to cause, from uncertainty to clarity. By embracing specificity in both documentation and coding, healthcare professionals ensure accurate reimbursement, contribute to robust data for research and public health, and, most importantly, support the delivery of precise and effective patient care.

Frequently Asked Questions (FAQs)

Q1: Can I use R94.5 as a primary diagnosis?
A: Yes, but only if the elevated LFTs are the primary reason for the encounter and no definitive diagnosis has been established. If a cause is known, you must code the cause.

Q2: What is the most specific code for “fatty liver”?
A: It depends on the documentation. If the provider specifies “non-alcoholic steatohepatitis” or “NASH,” use K75.81. If it’s simply “fatty liver” or “NAFLD” without mention of steatohepatitis, use K76.0. If it’s alcoholic, use a code from the K70 series.

Q3: How do I code for a patient with a history of hepatitis C that has been cured?
A: You would not code a current diagnosis of hepatitis C. Instead, use a personal history code: Z86.19 (Personal history of other infectious and parasitic diseases). If the cured HCV has led to a current complication like cirrhosis, you would code the cirrhosis (e.g., K74.69).

Q4: A patient’s LFTs are elevated due to metastatic cancer in the liver. Do I use a code from the K70-K77 range?
A: No. The primary diagnosis is the metastatic cancer. Code the primary neoplasm with metastasis to the liver (e.g., C78.7 for Secondary malignant neoplasm of liver). The elevated LFTs are a symptom of this underlying malignancy.

Q5: What is the difference between K74.60 (unspecified cirrhosis) and K74.69 (other cirrhosis)?
A: K74.60 is used when the provider documents “cirrhosis” but does not specify the type. K74.69 is used for other specific types of cirrhosis that don’t have their own unique code, such as “cryptogenic cirrhosis” or “mixed micronodular and macronodular cirrhosis.”

Additional Resources

1. The Official ICD-10-CM Guidelines for Coding and Reporting: Published annually by the CDC and CMS. This is the definitive source for coding rules.

2. American Hospital Association (AHA) Coding Clinic: Provides official advice and scenarios for ICD-10-CM coding.

3. American Association for the Study of Liver Diseases (AASLD): Provides clinical practice guidelines on the diagnosis and management of liver diseases, which inform proper documentation.

4. American Health Information Management Association (AHIMA): A key resource for professional education and standards in health information management and coding.

 

Author: The Medical Coding & Hepatology Insights Team
Disclaimer: The information contained in this article is intended for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or treatment, and before undertaking a new health care regimen. Never disregard professional medical advice or delay in seeking it because of something you have read in this publication. The authors and publishers are not responsible for any specific health or medical needs that may require medical supervision and are not liable for any damages or negative consequences from any treatment, action, application, or preparation, to any person reading or following the information in this article.